PMID

Data

Article Title

Organization

Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR¿ agonists.

Glaxosmithkline

(Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARß/d-selective ligand with inverse agonistic properties.

Philipps University

Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.

Kyorin Pharmaceutical

Selective peroxisome proliferator-activated receptord isosteric selenium agonists as potent anti-atherogenic agents in vivo.

Seoul National University

A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities.

Seoul National University

Glycine amides as PPARalpha agonists.

Bayer-Schering Pharma

Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.

The Genomics Institute of The Novartis Research Foundation

Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.

Glaxosmithkline

The discovery of equipotent PPARalpha/gamma dual activators.

Glaxosmithkline

Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.

Glaxosmithkline

Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.

Novo Nordisk

Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPAR? agonists.

Shionogi

Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.

Bayer Pharmaceuticals

Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.

University of Tokyo

Discovery and structure-based design of a new series of potent and selective PPAR? agonists utilizing a virtual screening method.

Shionogi

Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPAR?/? Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.

China Pharmaceutical University

Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.

Glaxosmithkline

Selective PPAR? Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD).

Mitobridge

Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis.

Glaxosmithkline

Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.

Glaxosmithkline

The PPARs: from orphan receptors to drug discovery.

Glaxo Wellcome Research & Development

A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.

Glaxo Wellcome Research & Development

Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.

Inception Sciences

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR)?/?/? Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Inventiva